Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | LSS | P48449 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2987624 | 1.00 | MEN1 (0.42) | MEN1CYP3A4ALOX15KMT2AMAPT | |
| SCHEMBL13949347 | 1.00 | MEN1 (0.42) | MEN1CYP3A4ALOX15KMT2AMAPT | |
| SCHEMBL13949345 | 1.00 | MEN1 (0.42) | MEN1CYP3A4ALOX15KMT2AMAPT | |
| SCHEMBL13949348 | 1.00 | MEN1 (0.42) | MEN1CYP3A4ALOX15KMT2AMAPT | |
| SCHEMBL13949349 | 1.00 | MEN1 (0.42) | MEN1CYP3A4ALOX15KMT2AMAPT | |
| SCHEMBL7536904 | 0.82 | LSS (0.33) | LSS | |
| SCHEMBL7536907 | 0.82 | LSS (0.33) | LSS | |
| SCHEMBL15978564 | 0.78 | LSS (0.41) | KMT2APTPN1LSS | |
| SCHEMBL13409658 | 0.74 | ALDH1A1 (0.42) | ALDH1A1PTPN1 | |
| SCHEMBL13409665 | 0.74 | ALDH1A1 (0.42) | ALDH1A1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7777084-B2 | Cyclopropanation process | GIVAUDAN SA (CH) | 2010-08-17 | — | — | US | disclosed |
| US-7777084-B2 | Cyclopropanation process | GIVAUDAN SA (CH) | 2010-08-17 | — | — | US | disclosed |
| US-7777084-B2 | Cyclopropanation process | GIVAUDAN SA (CH) | 2010-08-17 | — | — | US | disclosed |
| EP-1828087-B1 | CYCLOPROPANATION PROCESS | GIVAUDAN SA (CH) | 2008-12-03 | — | — | EP | disclosed |
| EP-1828087-B1 | CYCLOPROPANATION PROCESS | GIVAUDAN SA (CH) | 2008-12-03 | — | — | EP | disclosed |
| US-20080275256-A1 | Cyclopropanation Process | GIVAUDAN SA (CH) | 2008-11-06 | — | — | US | disclosed |
| US-20080275256-A1 | Cyclopropanation Process | GIVAUDAN SA (CH) | 2008-11-06 | — | — | US | disclosed |
| US-20080275256-A1 | Cyclopropanation Process | GIVAUDAN SA (CH) | 2008-11-06 | — | — | US | disclosed |
| EP-1828087-A1 | CYCLOPROPANATION PROCESS | Givaudan SA (CH) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006066436-A1 | CYCLOPROPANATION PROCESS | GIVAUDAN SA (CH) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275256-A1 | Cyclopropanation Process | C9, TRPA1, HACL2 | MEN1 2891/4885CYP3A4 380/4885ALOX15 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.